{"id":77,"date":"2014-08-05T15:44:40","date_gmt":"2014-08-05T13:44:40","guid":{"rendered":"https:\/\/www.remgro.com\/group-investments\/healthcare\/"},"modified":"2025-10-28T10:00:21","modified_gmt":"2025-10-28T08:00:21","slug":"healthcare","status":"publish","type":"page","link":"https:\/\/www.remgro.com\/group-investments\/healthcare\/","title":{"rendered":"Healthcare"},"content":{"rendered":"

[vc_section css=”.vc_custom_1698312295250{background: none !important;}”][vc_row css=”.vc_custom_1698308864507{background: none !important; margin-bottom: 2rem !important;}”][vc_column css=”.vc_custom_1729850196723{margin-bottom: 0px !important;padding-top: 10px !important;padding-bottom: 10px !important;}”][vc_column_text css=”.vc_custom_1760940574537{margin-bottom: 0px !important;}”]\n

\n
\n\n\n\n\n\n\n
\u00a0Contribution to headline earnings<\/th>\n30\u00a0June
\n2025
\nR\u00a0million<\/th>\n		30\u00a0June
\n2024
\nR\u00a0million<\/td>\n<\/tr>\n<\/thead>\n
\u00a0Mediclinic<\/td>\n2 386<\/td>\n1 515<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n[\/vc_column_text][\/vc_column][\/vc_row][vc_row equal_height=”yes” css=”.vc_custom_1729425855589{margin-bottom: 2rem !important;}”][vc_column width=”2\/3″][vc_column_text css=””]\n

Mediclinic Group Limited<\/p>\n

(Mediclinic)<\/p>\n

Effective interest: 50.0%<\/p>\n[\/vc_column_text][\/vc_column][vc_column width=”1\/3″][vc_column_text css=””]\"\"[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text css=””]Profile:<\/span> Mediclinic is a diversified international private healthcare services group, established in South Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia), and the Middle East.<\/p>\n

Hirslanden, the largest private healthcare provider in Switzerland, is recognised for clinical excellence and outstanding client experience. Hirslanden services approximately one-third of inpatients treated in Swiss private hospitals. The operation includes 17 hospitals and five day-case clinics.<\/p>\n

Mediclinic Southern Africa, one of the three largest private healthcare providers in the region, focusses on providing acute care, specialist-oriented, multi-disciplinary hospital services and related service offerings. The operation includes 50 hospitals, five subacute hospitals, six mental health facilities, 15 day-case clinics across South Africa, and 11 renal clinics.<\/p>\n

Mediclinic Middle East is established as a leading healthcare provider in the United Arab Emirates (UAE) with the majority of its operations in Dubai and Abu Dhabi (including Al Ain) offering clinical care of internationally recognised standards. The operation includes seven hospitals, one day-case clinic and 28 outpatient clinics.<\/p>\n

\n[\/vc_column_text][\/vc_column][\/vc_row][vc_row css=”.vc_custom_1730221406915{margin-top: 0px !important;margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”][vc_column css=”.vc_custom_1730221530633{margin-top: 0px !important;margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”][vc_row_inner][vc_column_inner width=”1\/2″ css=”.vc_custom_1730221552364{margin-top: 0px !important;margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”][vc_column_text css=””]\n

Corporate information<\/p>\n

Equity valuation at 30 June 2025:<\/span> $4 676 million<\/div>\n
Unlisted<\/span><\/div>\n
Chief Executive Officer:<\/span> R van der Merwe<\/div>\n
Remgro nominated directors:<\/span> J J Durand, A Elias, C P F Vosloo and S Crouse (alternate)<\/div>\n
Website:<\/span> www.mediclinic.com<\/a><\/div>\n

 <\/p>\n

Sustainability measures<\/p>\n

CSI spend: <\/span>R141 million<\/div>\n
Training spend: <\/span>R205 million<\/div>\n
Number of employees: <\/span>38 338<\/div>\n
BBBEE status: <\/span>Level 2<\/div>\n
Environmental aspect: <\/span>Scope 1 and 2 emissions of 172 817 tonnes CO2<\/sub>e<\/div>\n[\/vc_column_text][\/vc_column_inner][vc_column_inner width=”1\/2″ css=”.vc_custom_1730221569919{margin-top: 0px !important;margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”][vc_column_text css=””]\n
\n\n\n\n\n\n\n\n\n\n\n
\u00a0Financial highlights<\/th>\nYear ended 31 March<\/th>\n<\/th>\n<\/tr>\n
2025
\n$ million<\/th>\n		2024(1)<\/sup>
\n$ million<\/th>\n		%
\nchange<\/em><\/th>\n<\/tr>\n<\/thead>\n
\u00a0Revenue<\/td>\n4 818<\/strong><\/td>\n4 592<\/strong><\/td>\n4.9<\/em><\/td>\n<\/tr>\n
\u00a0Adjusted EBITDA<\/td>\n737<\/strong><\/td>\n673<\/strong><\/td>\n9.5<\/em><\/td>\n<\/tr>\n
\u00a0Adjusted operating profit<\/td>\n415<\/strong><\/td>\n356<\/strong><\/td>\n16.6<\/em><\/td>\n<\/tr>\n
\u00a0Adjusted earnings<\/td>\n239<\/strong><\/td>\n197<\/strong><\/td>\n21.3<\/em><\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n
(1)<\/em><\/sup><\/td>\nComparatives were for Mediclinic, now restated to Manta Bidco.<\/em><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][\/vc_section][vc_row css=”.vc_custom_1730221502833{margin-top: 0px !important;margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”][vc_column][vc_column_text css=””]\n
\n

Mediclinic\u2019s contribution to Remgro\u2019s headline earnings, which includes the contribution of Manta Bidco Limited (Manta Bidco), amounted to R2\u00a0386\u00a0million (2024: R1\u00a0515\u00a0million), representing an increase of 57.5%. As a result of the Mediclinic acquisition (being the acquisition, through Remgro\u2019s 50% interest in Manta Bidco, which is jointly owned by Remgro and MSC Mediterranean Shipping Company SA (MSC), of the entire issued ordinary share capital of Mediclinic), Remgro\u2019s indirect interest in Mediclinic increased from 44.6% to 50.0% (or by 5.4%) during June 2023. As Mediclinic has a March year-end, the comparative year included Remgro\u2019s portion of the Mediclinic results for the two months ended 31 May 2023 at 44.6% and for the ten months to 31\u00a0March\u00a02024 at 50.0%. Mediclinic\u2019s contribution in the comparative year also included transaction costs of R165 million relating to the Mediclinic acquisition. Excluding these transaction costs, Mediclinic\u2019s contribution to headline earnings increased from R1\u00a0680\u00a0million to R2\u00a0386\u00a0million (or 42.0%).<\/p>\n

Mediclinic (including Manta Bidco) reports adjusted earnings, which removes volatility associated with certain types of significant income and charges from headline earnings, to assess financial and operational performance and as a method to provide investors and analysts with complementary information to better understand its financial performance. These adjustments include the portion of the above-mentioned transaction costs incurred by Mediclinic and the comparative year also included an increase in a redemption liability of $40 million relating to the acquisition of Hirslanden La Colline Grangettes SA.<\/p>\n

Mediclinic delivered good results for the year ended 31\u00a0March\u00a02025 against a backdrop of a persistently challenging operating environment, particularly in Switzerland where simultaneous pressure on prices and operating costs is impacting the performance of healthcare service providers. Mediclinic\u2019s board and management team are responding to these challenges through a comprehensive plan aimed at reducing costs, improving efficiencies, and adapting the business to a path of sustainability and growth.<\/p>\n

Mediclinic\u2019s performance for the year ended 31\u00a0March\u00a02025 was driven by strong volume growth across all divisions. Mediclinic group revenue was up 5% at $4 818 million (2024: $4 592 million) and up 4% in constant currency terms. Inpatient admissions and day cases grew by 1.5% and 3.2%, respectively.<\/p>\n

Adjusted EBITDA was up 9% at $737\u00a0million (2024: $673\u00a0million) and up 9% in constant currency terms. Adjusted EBITDA margin was 15.3% (2024: 14.7%), reflecting good revenue growth and cost efficiency, partially offset by higher consumables and supply costs mainly because of ongoing mix changes. Adjusted operating profit was up 16% at $415\u00a0million (2024: $356\u00a0million) and up 16% in constant currency terms. Adjusted earnings were up 21% at $239\u00a0million (2024: $197\u00a0million). Adjusted depreciation and amortisation were up 2% to $323\u00a0million (2024: $318\u00a0million), reflecting ongoing investment in facilities and equipment across the three divisions, and adjusted net finance cost was up 1% at $107\u00a0million (2024: $106\u00a0million), which further explains the increases in adjusted operating profit and adjusted earnings.<\/p>\n

Mediclinic delivered a cash conversion of 104% (2024: 92%), marginally ahead of the targeted 90\u2013100%, mainly due to improved collections in Switzerland and the Middle East.<\/p>\n

Switzerland\u2019s revenue for the year increased by 2% to CHF1 940\u00a0million (2024: CHF1 905\u00a0million), reflecting good growth in inpatient admissions of 2.2%. The general insurance mix was marginally higher at 52.6% (2024: 52.1%) as growth in generally insured admissions exceeded that of supplementary insurance. Growth in inpatient admissions, partly offset by a decrease in the average length of stay by 3.4%, resulted in an improved occupancy rate of 58.8% (2024: 58.1%). Outpatient and day-case revenue was broadly flat at CHF417\u00a0million (2024: CHF408\u00a0million), contributing some 21% (2024: 21%) to total revenue during the period. The revenue growth delivered a 4% increase in adjusted EBITDA to CHF266 million (2024: CHF255\u00a0million). The adjusted EBITDA margin increased from 13.4% to 13.7%, reflecting disciplined cost management, offset by higher consumables and supply costs driven by increased volumes and mix changes.<\/p>\n

Southern Africa\u2019s revenue for the year increased by 8% to R22\u00a0369\u00a0million (2024: R20\u00a0786\u00a0million) in a challenging economic environment. In comparison with the prior year, paid patient days (PPDs) increased by 1.2%, with day cases increasing by 3.2%. Occupancy improved to an average of 67.7% (2024: 67.4%) as the admission growth was partially offset by a 0.3% reduction in average length of stay. Average revenue per bed day was up 6.5% compared with the prior year, reflecting year-on-year price increases and speciality mix changes. Adjusted EBITDA increased by 8% to R4\u00a0097\u00a0million (2024: R3\u00a0784\u00a0million), resulting in an adjusted EBITDA margin of 18.3% (2024: 18.2%).<\/p>\n

The Middle East revenue for the year increased by 5% to AED5 135\u00a0million (2024: AED4 892\u00a0million), driven by continued growth in client activity and increased pharmacy revenue. Inpatient admissions and day cases were up 4.8% and 3.5%, respectively, and outpatient cases increased by 1.0%. Adjusted EBITDA increased by 10% to AED788\u00a0million (2024: AED714\u00a0million), driven by revenue growth and strong cost discipline. The adjusted EBITDA margin increased to 15.4% (2024: 14.6%).<\/p>\n[\/vc_column_text][\/vc_column][\/vc_row]\n<\/div>","protected":false},"excerpt":{"rendered":"

[vc_section css=”.vc_custom_1698312295250{background: none !important;}”][vc_row css=”.vc_custom_1698308864507{background: none !important; margin-bottom: 2rem !important;}”][vc_column css=”.vc_custom_1729850196723{margin-bottom: 0px !important;padding-top: 10px !important;padding-bottom: 10px !important;}”][vc_column_text css=”.vc_custom_1760940574537{margin-bottom: 0px !important;}”] \u00a0Contribution to headline earnings 30\u00a0June 2025 R\u00a0million 30\u00a0June 2024 R\u00a0million \u00a0Mediclinic 2 386 1 515 [\/vc_column_text][\/vc_column][\/vc_row][vc_row equal_height=”yes” css=”.vc_custom_1729425855589{margin-bottom: 2rem !important;}”][vc_column width=”2\/3″][vc_column_text css=””] Mediclinic Group Limited (Mediclinic) Effective interest: 50.0% [\/vc_column_text][\/vc_column][vc_column width=”1\/3″][vc_column_text css=””][\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text css=””]Profile: Mediclinic is… Read more »<\/a><\/p>\n","protected":false},"author":5,"featured_media":0,"parent":10,"menu_order":25,"comment_status":"closed","ping_status":"closed","template":"page-full-width.php","meta":{"footnotes":""},"class_list":["post-77","page","type-page","status-publish","hentry"],"yoast_head":"\nHealthcare - Remgro Limited<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.remgro.com\/group-investments\/healthcare\/\" \/>\n<meta property=\"og:locale\" content=\"af_ZA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Healthcare - Remgro Limited\" \/>\n<meta property=\"og:description\" content=\"[vc_section css=”.vc_custom_1698312295250{background: none !important;}”][vc_row css=”.vc_custom_1698308864507{background: none !important; margin-bottom: 2rem !important;}”][vc_column css=”.vc_custom_1729850196723{margin-bottom: 0px !important;padding-top: 10px !important;padding-bottom: 10px !important;}”][vc_column_text css=”.vc_custom_1760940574537{margin-bottom: 0px !important;}”] \u00a0Contribution to headline earnings 30\u00a0June 2025 R\u00a0million 30\u00a0June 2024 R\u00a0million \u00a0Mediclinic 2 386 1 515 [\/vc_column_text][\/vc_column][\/vc_row][vc_row equal_height=”yes” css=”.vc_custom_1729425855589{margin-bottom: 2rem !important;}”][vc_column width=”2\/3″][vc_column_text css=””] Mediclinic Group Limited (Mediclinic) Effective interest: 50.0% [\/vc_column_text][\/vc_column][vc_column width=”1\/3″][vc_column_text css=””][\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text css=””]Profile: Mediclinic is... Read more »\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.remgro.com\/group-investments\/healthcare\/\" \/>\n<meta property=\"og:site_name\" content=\"Remgro Limited\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-28T08:00:21+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/ince-dev-2023.dev.ince.co.za\/www.remgro.com\/wp-content\/images\/2024\/logos\/mediclinic.png\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.remgro.com\\\/group-investments\\\/healthcare\\\/\",\"url\":\"https:\\\/\\\/www.remgro.com\\\/group-investments\\\/healthcare\\\/\",\"name\":\"Healthcare - Remgro Limited\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.remgro.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.remgro.com\\\/group-investments\\\/healthcare\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.remgro.com\\\/group-investments\\\/healthcare\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.remgro.com\\\/wp-content\\\/images\\\/2024\\\/logos\\\/mediclinic.png\",\"datePublished\":\"2014-08-05T13:44:40+00:00\",\"dateModified\":\"2025-10-28T08:00:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.remgro.com\\\/group-investments\\\/healthcare\\\/#breadcrumb\"},\"inLanguage\":\"af-ZA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.remgro.com\\\/group-investments\\\/healthcare\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"af-ZA\",\"@id\":\"https:\\\/\\\/www.remgro.com\\\/group-investments\\\/healthcare\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.remgro.com\\\/wp-content\\\/images\\\/2024\\\/logos\\\/mediclinic.png\",\"contentUrl\":\"https:\\\/\\\/www.remgro.com\\\/wp-content\\\/images\\\/2024\\\/logos\\\/mediclinic.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.remgro.com\\\/group-investments\\\/healthcare\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Group investments\",\"item\":\"https:\\\/\\\/www.remgro.com\\\/group-investments\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Healthcare\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.remgro.com\\\/#website\",\"url\":\"https:\\\/\\\/www.remgro.com\\\/\",\"name\":\"Remgro Limited\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.remgro.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.remgro.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"af-ZA\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.remgro.com\\\/#organization\",\"name\":\"Remgro Limited\",\"url\":\"https:\\\/\\\/www.remgro.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"af-ZA\",\"@id\":\"https:\\\/\\\/www.remgro.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.remgro.com\\\/wp-content\\\/uploads\\\/2016\\\/03\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/www.remgro.com\\\/wp-content\\\/uploads\\\/2016\\\/03\\\/logo.jpg\",\"width\":337,\"height\":109,\"caption\":\"Remgro Limited\"},\"image\":{\"@id\":\"https:\\\/\\\/www.remgro.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Healthcare - Remgro Limited","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.remgro.com\/group-investments\/healthcare\/","og_locale":"af_ZA","og_type":"article","og_title":"Healthcare - Remgro Limited","og_description":"[vc_section css=”.vc_custom_1698312295250{background: none !important;}”][vc_row css=”.vc_custom_1698308864507{background: none !important; margin-bottom: 2rem !important;}”][vc_column css=”.vc_custom_1729850196723{margin-bottom: 0px !important;padding-top: 10px !important;padding-bottom: 10px !important;}”][vc_column_text css=”.vc_custom_1760940574537{margin-bottom: 0px !important;}”] \u00a0Contribution to headline earnings 30\u00a0June 2025 R\u00a0million 30\u00a0June 2024 R\u00a0million \u00a0Mediclinic 2 386 1 515 [\/vc_column_text][\/vc_column][\/vc_row][vc_row equal_height=”yes” css=”.vc_custom_1729425855589{margin-bottom: 2rem !important;}”][vc_column width=”2\/3″][vc_column_text css=””] Mediclinic Group Limited (Mediclinic) Effective interest: 50.0% [\/vc_column_text][\/vc_column][vc_column width=”1\/3″][vc_column_text css=””][\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text css=””]Profile: Mediclinic is... Read more »","og_url":"https:\/\/www.remgro.com\/group-investments\/healthcare\/","og_site_name":"Remgro Limited","article_modified_time":"2025-10-28T08:00:21+00:00","og_image":[{"url":"http:\/\/ince-dev-2023.dev.ince.co.za\/www.remgro.com\/wp-content\/images\/2024\/logos\/mediclinic.png","type":"","width":"","height":""}],"twitter_misc":{"Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.remgro.com\/group-investments\/healthcare\/","url":"https:\/\/www.remgro.com\/group-investments\/healthcare\/","name":"Healthcare - Remgro Limited","isPartOf":{"@id":"https:\/\/www.remgro.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.remgro.com\/group-investments\/healthcare\/#primaryimage"},"image":{"@id":"https:\/\/www.remgro.com\/group-investments\/healthcare\/#primaryimage"},"thumbnailUrl":"https:\/\/www.remgro.com\/wp-content\/images\/2024\/logos\/mediclinic.png","datePublished":"2014-08-05T13:44:40+00:00","dateModified":"2025-10-28T08:00:21+00:00","breadcrumb":{"@id":"https:\/\/www.remgro.com\/group-investments\/healthcare\/#breadcrumb"},"inLanguage":"af-ZA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.remgro.com\/group-investments\/healthcare\/"]}]},{"@type":"ImageObject","inLanguage":"af-ZA","@id":"https:\/\/www.remgro.com\/group-investments\/healthcare\/#primaryimage","url":"https:\/\/www.remgro.com\/wp-content\/images\/2024\/logos\/mediclinic.png","contentUrl":"https:\/\/www.remgro.com\/wp-content\/images\/2024\/logos\/mediclinic.png"},{"@type":"BreadcrumbList","@id":"https:\/\/www.remgro.com\/group-investments\/healthcare\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Group investments","item":"https:\/\/www.remgro.com\/group-investments\/"},{"@type":"ListItem","position":2,"name":"Healthcare"}]},{"@type":"WebSite","@id":"https:\/\/www.remgro.com\/#website","url":"https:\/\/www.remgro.com\/","name":"Remgro Limited","description":"","publisher":{"@id":"https:\/\/www.remgro.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.remgro.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"af-ZA"},{"@type":"Organization","@id":"https:\/\/www.remgro.com\/#organization","name":"Remgro Limited","url":"https:\/\/www.remgro.com\/","logo":{"@type":"ImageObject","inLanguage":"af-ZA","@id":"https:\/\/www.remgro.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.remgro.com\/wp-content\/uploads\/2016\/03\/logo.jpg","contentUrl":"https:\/\/www.remgro.com\/wp-content\/uploads\/2016\/03\/logo.jpg","width":337,"height":109,"caption":"Remgro Limited"},"image":{"@id":"https:\/\/www.remgro.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.remgro.com\/af\/wp-json\/wp\/v2\/pages\/77","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.remgro.com\/af\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.remgro.com\/af\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.remgro.com\/af\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.remgro.com\/af\/wp-json\/wp\/v2\/comments?post=77"}],"version-history":[{"count":129,"href":"https:\/\/www.remgro.com\/af\/wp-json\/wp\/v2\/pages\/77\/revisions"}],"predecessor-version":[{"id":22809,"href":"https:\/\/www.remgro.com\/af\/wp-json\/wp\/v2\/pages\/77\/revisions\/22809"}],"up":[{"embeddable":true,"href":"https:\/\/www.remgro.com\/af\/wp-json\/wp\/v2\/pages\/10"}],"wp:attachment":[{"href":"https:\/\/www.remgro.com\/af\/wp-json\/wp\/v2\/media?parent=77"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}